{"id":2874,"date":"2025-01-15T11:05:45","date_gmt":"2025-01-15T10:05:45","guid":{"rendered":"https:\/\/www.natixispartners.be\/?post_type=transaction&#038;p=2874"},"modified":"2025-03-12T17:10:27","modified_gmt":"2025-03-12T16:10:27","slug":"bone-therapeutics-ma-advisory","status":"publish","type":"transaction","link":"https:\/\/www.natixispartners.be\/fr\/transaction\/bone-therapeutics-ma-advisory\/","title":{"rendered":"Bone Therapeutics &#8211; M&amp;A Advisory"},"content":{"rendered":"\n<p>Bone Therapeutics (Euronext Brussels and Paris: BOTHE) &#8211; a cell therapy company addressing unmet medical needs in orthopedics,&nbsp; and Medsenic &#8211; a clinical stage biopharmaceutical specialized in the treatment of auto-immune diseases, announced they have reached an agreement to combine their activities. The business combination will result in the creation of BioSenic.<\/p>\n\n\n\n<p>Natixis Partners Belgium acted as M&amp;A advisor to the Board of Directors of Bone Therapeutics.<\/p>\n","protected":false},"featured_media":0,"template":"","transaction-year":[69],"class_list":["post-2874","transaction","type-transaction","status-publish","hentry","transaction-year-69"],"_links":{"self":[{"href":"https:\/\/www.natixispartners.be\/fr\/wp-json\/wp\/v2\/transaction\/2874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.natixispartners.be\/fr\/wp-json\/wp\/v2\/transaction"}],"about":[{"href":"https:\/\/www.natixispartners.be\/fr\/wp-json\/wp\/v2\/types\/transaction"}],"wp:attachment":[{"href":"https:\/\/www.natixispartners.be\/fr\/wp-json\/wp\/v2\/media?parent=2874"}],"wp:term":[{"taxonomy":"transaction-year","embeddable":true,"href":"https:\/\/www.natixispartners.be\/fr\/wp-json\/wp\/v2\/transaction-year?post=2874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}